On March 15, 2010 Vernalis plc (LSE: VER) reported the achievement of a milestone under the company’s collaboration with Novartis on the oncology target Hsp90 (Press release, Cancer Research Technology, MAR 15, 2010, View Source [SID1234523528]). The $3 million milestone is triggered by the first dosing in a Phase II proof of concept clinical trial of AUY-922, an Hsp90 inhibitor, in a range of solid tumours.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Ian Garland, CEO of Vernalis said "We are delighted that our programme with Novartis has progressed into Phase II and we look forward to the results of the current Phase II proof of concept study which Novartis has indicated are targeted for 2010".

Visit the Vernalis website here.